Traditional Chinese Medicine in the treatment of recurrent respiratory tract infections in children: an overview of systematic reviews and Meta-analyses
作者机构：School of Basic Medical SciencesGuangxi University of Chinese Medicine School of Basic Medical SciencesGuangxi University of Chinese MedicineGuangxi Key Laboratory of Marine Drugs Department of PharmacyHainan Traditional Chinese Medicine Hospital
出 版 物：《Journal of Traditional Chinese Medicine》 (中医杂志(英文版))
年 卷 期：2024年第44卷第5期
页 面：871-884页
核心收录：
学科分类：1005[医学-中医学] 100510[医学-中医儿科学] 10[医学]
基 金：the National Natural Science Foundation of China:Study on the Mechanisms of Multi-target Immunomodulation by Hydrolyzed Nanzhu Tablets in Children with RRTI Based on scRNAseq Technology (No.82060825) Huang Danian-type Teacher Team of National Universities-Teacher Team of Basic Course of Chinese and Western Medicine (Ministry of Education Teacher Letter No.2) Guangxi Famous Chinese Medicine Doctor Lin Jiang Inheritance Studio (Gui TCM Science and Education Development No.6) Guangxi First-class Discipline of Chinese Medicine (Gui Textbook Research No.1) Guangxi Interdisciplinary Innovation Team of Chinese Medicine (GZKJ2302)
主 题：Meta-analysis child medicine, Chinese traditional randomized controlled trial respiratory tract infections systematic review
摘 要：OBJECTIVE: To evaluate and summarise the evidence from published Meta-analyses/systematic reviews(MAs/SRs) of Traditional Chinese Medicine(TCM) in the treatment of recurrent respiratory tract infections(RRTIs) and to provide a scientific basis for the clinical treatment of RRTIs with TCM. METHODS: Studies were retrieved from Chinese and English databases including the China National Knowledge Infrastructure, Wanfang database, China Science and Technology Journal Database, SinoM ed, PubM ed, Web of Science, the Cochrane Library and EMbase from their establishment date to March 2023. Involved studies were screened, extracted, and evaluated for quality by two researchers independently. The a measurement tool to assess systematic reviews(AMSTAR) 2 scale was used for methodological quality evaluation, as well as the preferred reporting items for systematic reviews and Meta-analyses(PRISMA) 2020 statement for report quality evaluation, the risk of bias in systematic reviews(ROBIS) tool for risk of bias, and the grading of recommendations, assessment, development and evaluation(GRADE) quality assessment tool for evidence quality. RESULTS: Twenty MAs/SRs studies were included, including analyses of 274 original studies involving 38 335 patients with RRTIs. The AMSTAR 2 scale evaluation results showed that 19 studies were of very low quality and one of moderate quality. The ROBIS evaluation results showed that 11 MAs/SRs were at high risk and nine at low risk of bias. The PRISMA 2020 report quality showed the included studies had scores between 23.5 and 35.5, among them one with high quality, 17 with moderate quality and two with low quality. The GRADE system results showed that among 126 outcome indicators, only 17 had moderate quality of evidence, 27 had low quality, 82 had very low quality, and none had high quality. CONCLUSIONS: The MAs/SRs methodological quality of using TCM for treatment RRTIs is generally poor, the quality of reports as well as of evidence is generall
同方期刊数据库